The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
 
Yunpeng Yang
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Wenfeng Fang
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Qingqing Cai
No Relationships to Disclose
 
Zhi-Ming Li
No Relationships to Disclose
 
Hongyun Zhao
No Relationships to Disclose
 
Yuanyuan Zhao
No Relationships to Disclose
 
Ting Zhou
No Relationships to Disclose
 
Shaodong Hong
No Relationships to Disclose
 
Yaxiong Zhang
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose